SCHEDULE 13G: Biotechnology Value Fund Group Discloses Significant Stake in RAPT Therapeutics
Schedule 13G Filing
A group of investment entities led by Mark N. Lampert, including Biotechnology Value Fund L.P. and its affiliates, has disclosed a combined beneficial ownership of 8.7% of RAPT Therapeutics, Inc.'s common stock, including shares underlying pre-funded warrants.
Summary
- A group of investment entities, including Biotechnology Value Fund L.P. (BVF), BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively referred to as the "Reporting Persons," have filed a Schedule 13G.
- As of December 27, 2024, the date requiring the filing, and January 6, 2025, the Reporting Persons and a Partners managed account beneficially owned an aggregate of 11,764,000 shares of RAPT Therapeutics, Inc. common stock.
- This aggregate ownership represents approximately 8.7% of the outstanding common stock of RAPT Therapeutics, Inc.
- The ownership includes 2,526,444 shares underlying Pre-Funded Common Stock Purchase Warrants, which are immediately exercisable at an exercise price of $0.0001 per share and do not expire.
- The Pre-Funded Warrants are subject to a 9.99% beneficial ownership blocker, which did not limit their exercise as of January 6, 2025.
- The percentage of class calculation is based on 34,958,253 shares outstanding as of November 7, 2024, adjusted for a December 23, 2024 exchange of 2,951,425 shares for Pre-Funded Warrants, the issuance of 100,000,000 shares on December 23, 2024, and the 2,526,444 shares underlying the Pre-Funded Warrants held by the Reporting Persons.
- The Reporting Persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership by an investment group. It does not contain positive or negative operational or financial news about the company itself, nor does it express a sentiment about the company's prospects beyond the investment itself.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant ownership stake by an institutional investor group provides transparency regarding the company's shareholder base and may influence market perception of the stock.
- Company Management: Awareness of a large institutional holder may influence strategic decisions or engagement with the investor group.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date of 34,958,253 Shares outstanding as reported in Issuer's Quarterly Report on Form 10-Q filed on November 12, 2024. |
| 2024-11-12 | Date of Issuer's Quarterly Report on Form 10-Q filing. |
| 2024-12-23 | Date of exchange agreement for 2,951,425 shares for Pre-Funded Warrants. |
| 2024-12-23 | Date of Securities Purchase Agreement for 100,000,000 shares issued and sold by the Issuer, as reported in Form 8-K. |
| 2024-12-27 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-01-06 | Date of filing of the Schedule 13G and Joint Filing Agreement. |
Keywords
RAPT Therapeutics, Schedule 13G, Beneficial Ownership, Biotechnology Value Fund, Mark N. Lampert, Common Stock, Pre-Funded Warrants, SEC Filing, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.